Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

108.61 -1.40 (-1.27%)
Official Closing Price Updated: 7:00 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
The 3 Best Defensive Stocks to Buy in June 2023
With market and economic concerns rising, investors may find comfort targeting these ideas for the best defensive stocks to buy. 
Via InvestorPlace
This Is What Whales Are Betting On Merck & Co
 
Via Benzinga
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Merck & Co Inc (NYSE: MRK) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA).  
Via Benzinga
Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts
 
Via Benzinga
Merck Delivers First Legal Blow To Biden's Medicare Negotiation Plan, Calling It A 'Sham'
The company hopes to block elements of the Inflation Reduction Act focused on the prices Medicare pays for drugs. 
Via Investor's Business Daily
Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%
 
Via Benzinga
Analyst Ratings for Merck & Co
 
Via Benzinga
Why PDS Biotech Shares Are Jumping Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years
 
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
BioNTech is testing out a next-generation form of Yervoy, hoping to reduce side effects. 
Via Investor's Business Daily
3 Undervalued Dow Stocks to Buy Before Wall Street Does
The Street is down on the blue-chip index, but these undervalued Dow Jones stocks should generate big profits for long-term investors. 
Via InvestorPlace
Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Anastasia Amoroso of JPMorgan Private Bank named iShares 7-10 Year Treasury Bond ETF (NASDAQ: IEF) 
Via Benzinga
Looking At Merck & Co's Recent Unusual Options Activity
 
Via Benzinga
7 Dividend Stocks to Buy (and Never Sell)
Each representing high-quality at reasonable prices, consider each of these seven some of the best long-term dividend stocks to buy. 
Via InvestorPlace
3 Innovative Growth Stocks to Buy for Next-Gen Profits
These are the innovative growth stocks for future profits as they represent companies investing significantly in research and development. 
Via InvestorPlace
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
A surge in price for shares of Nvidia Corporation (NASDAQ: NVDA) after the company’s quarterly earnings results and guidance has put the semiconductor company in the elusive $1 trillion market... 
Via Benzinga
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
These two pharmaceutical companies have created value for shareholders. 
Via The Motley Fool
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
Roche tested its treatment in patients with liver cancer and found "meaningful" results. 
Via Investor's Business Daily
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Benzinga 
Via Benzinga
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
 
Via Benzinga
After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer
 
Via Benzinga
7 Stocks That Could Be the Next $2 Trillion-Dollar Companies
AI, the cloud transition and success in the pharmaceutical sector will help these firms become future $2 trillion companies. 
Via InvestorPlace
3 Undervalued Pharma Stocks to Buy for High Total Returns
These are the undervalued pharma stocks to buy as they represent companies investing heavily in research to boost the product pipeline. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs
Investors are busy looking at tech stocks, but they should be looking for healthcare stocks to buy, as this group powers to new highs. 
Via InvestorPlace
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
Immutep Limited's (NASDAQ: IMMP) lead candidate — a soluble LAG-3 protein, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) — 
Via Benzinga
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
In a rare move to block a large pharma deal, the U.S. 
Via Benzinga
3 Penny Stocks That Could Make You a Millionaire by 2025
These are the best penny stocks to buy if you are targeting multibagger returns by 2025 with high price targets by analysts. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.